On July 1, 2025, Apellis Pharmaceuticals, Inc., a global biopharmaceutical company that develops life-changing therapies for challenging diseases, announced a capped royalty purchase agreement with Swedish Orphan Biovitrum AB (Sobi) under which Apellis will receive up to $300 million in exchange for a 90% reduction in ex-US royalties on sales by Sobi of Aspaveli® (systemic pegcetacoplan) until defined caps are achieved, after which 100% of such ex-US royalties will again become payable to Apellis. Aspaveli® is approved in the European Union and other countries globally (and in the US, where Apellis retains exclusive commercialization rights and markets the product as EMPAVELI®) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The product is currently under review in the European Union and the US for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare kidney diseases. 

The WilmerHale team advising Apellis included Stuart Falber, Steven Barrett, George Shuster, Nathan Moore, Scott Lunin, Mat Trachok, Katharine Patterson and Michaela Rosen.